meta-analysis is ranked among the highest-quality study designs, objective assessment criteria specific to meta-analysis have not been reported. As meta-analysis is complex in structure, we developed the Quality Score, which assesses the quality and format of meta-analysis. In this study, we attempted to assess the structure and quality of meta-analysis articles on type 2 diabetes. meta-analysis 2 diabetes from PubMed and the Cochrane Library. We then assessed the structure (PRISMA statement) and quality (the Quality Score) of the articles found by assigning scores. We further extracted articles above a certain level, and analyzed and organized the data with statistically significant differences. The initial search for meta-analysis articles identified 217 articles from PubMed and 25 from the Cochrane Library. Eight of the 25 articles from the Cochrane Library were also found among the articles from PubMed. Of the resultant 234 articles retrieved by the search formula, 44 were studied. The assessment score (0 – 100) for the structure (PRISMA statement) of meta-analysis was 60.2 ± 22.0 ％ (Mean ± SD), while the Quality Score was 53.0 ± 18.9 ％ . This study showed that the assessment of the quality of meta-analysis articles is linked to the assessment of the structure of the articles. In order to produce the great effect expected from diabetes medications, healthcare professionals are required to go beyond medication management and offer a wide range of therapeutic management. To do this, management priority should be given to items with secured evidence.
{"title":"Assessment and Analysis of the Assessment Criteria for Meta-Analysis Articles:─ Management of Diabetes Pharmacotherapy Based on Meta-Analysis Articles ─","authors":"Tomoka Osumi, H. Iijima","doi":"10.5649/JJPHCS.39.347","DOIUrl":"https://doi.org/10.5649/JJPHCS.39.347","url":null,"abstract":"meta-analysis is ranked among the highest-quality study designs, objective assessment criteria specific to meta-analysis have not been reported. As meta-analysis is complex in structure, we developed the Quality Score, which assesses the quality and format of meta-analysis. In this study, we attempted to assess the structure and quality of meta-analysis articles on type 2 diabetes. meta-analysis 2 diabetes from PubMed and the Cochrane Library. We then assessed the structure (PRISMA statement) and quality (the Quality Score) of the articles found by assigning scores. We further extracted articles above a certain level, and analyzed and organized the data with statistically significant differences. The initial search for meta-analysis articles identified 217 articles from PubMed and 25 from the Cochrane Library. Eight of the 25 articles from the Cochrane Library were also found among the articles from PubMed. Of the resultant 234 articles retrieved by the search formula, 44 were studied. The assessment score (0 – 100) for the structure (PRISMA statement) of meta-analysis was 60.2 ± 22.0 ％ (Mean ± SD), while the Quality Score was 53.0 ± 18.9 ％ . This study showed that the assessment of the quality of meta-analysis articles is linked to the assessment of the structure of the articles. In order to produce the great effect expected from diabetes medications, healthcare professionals are required to go beyond medication management and offer a wide range of therapeutic management. To do this, management priority should be given to items with secured evidence.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"6 1","pages":"347-355"},"PeriodicalIF":0.0,"publicationDate":"2013-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72655886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-12-10DOI: 10.5649/JJPHCS1975.26.577
斎藤 百枝美, 渡辺 真知子, 暁子 五十嵐, 浩 尾形, 清人 江戸
The masking effects of BMI-40 on six kinds of bitter tasting medicines were investigated. As a result, BMI-40 alone significantly masked the bitterness of the ground Polymyxin B sulfate tablet (gPL-B). Thereafter, the masking effects of BMI-40 and flavored BMI-40 (with 10% milk cocoa+ 10% sugar) on gPL-B (a hundred thousand U/mL) were compared with those of BMI-60 and flavored BMI-60. After increasing the concentration of BMI-40 by 4%, the masking effects of BMI-40 were same as those of BMI-60 and both were below the threshold of bitterness which was reported to be 3.0 point (BMI-40: 2.5±0.3, BMI-60: 2.3±0.3). On the other hand, flavored BMI-40 was more effective than flavored BMI-60 at a 1-4% additional concentration (p<0.001), and its bitterness intensity was below the threshold (2.0±0.3-1.0±0).The mechanism of masking bitterness by using BMI-40, which contained about 50% branched dextran, was next investigated. At a 1% concentration, the rate of bitterness intensity of BMI-40 on gPL-B decreased after adding milk cocoa but not after adding sugar in comparison with that of BMI-60 (BMI-40: 42.5%, BMI-60: 64.6%).The masking effects of 3%, 5% branched dextran, which contained BMI-40 but not BMI-60, significantly increased by adding milk cocoa, while branched dextran alone was not effective.These results suggested that 1% flavored BMI-40 (with 10% milk cocoa and 10% sugar) is clinically useful for masking the bitterness of gPL-B. Furthermore, the masking mechanism of BMI-40 is also considered to be different from that of BMI-60.
{"title":"ベネコートBMI-40とBMI-60との苦味マスキング効果の比較","authors":"斎藤 百枝美, 渡辺 真知子, 暁子 五十嵐, 浩 尾形, 清人 江戸","doi":"10.5649/JJPHCS1975.26.577","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.577","url":null,"abstract":"The masking effects of BMI-40 on six kinds of bitter tasting medicines were investigated. As a result, BMI-40 alone significantly masked the bitterness of the ground Polymyxin B sulfate tablet (gPL-B). Thereafter, the masking effects of BMI-40 and flavored BMI-40 (with 10% milk cocoa+ 10% sugar) on gPL-B (a hundred thousand U/mL) were compared with those of BMI-60 and flavored BMI-60. After increasing the concentration of BMI-40 by 4%, the masking effects of BMI-40 were same as those of BMI-60 and both were below the threshold of bitterness which was reported to be 3.0 point (BMI-40: 2.5±0.3, BMI-60: 2.3±0.3). On the other hand, flavored BMI-40 was more effective than flavored BMI-60 at a 1-4% additional concentration (p<0.001), and its bitterness intensity was below the threshold (2.0±0.3-1.0±0).The mechanism of masking bitterness by using BMI-40, which contained about 50% branched dextran, was next investigated. At a 1% concentration, the rate of bitterness intensity of BMI-40 on gPL-B decreased after adding milk cocoa but not after adding sugar in comparison with that of BMI-60 (BMI-40: 42.5%, BMI-60: 64.6%).The masking effects of 3%, 5% branched dextran, which contained BMI-40 but not BMI-60, significantly increased by adding milk cocoa, while branched dextran alone was not effective.These results suggested that 1% flavored BMI-40 (with 10% milk cocoa and 10% sugar) is clinically useful for masking the bitterness of gPL-B. Furthermore, the masking mechanism of BMI-40 is also considered to be different from that of BMI-60.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"102 1","pages":"577-583"},"PeriodicalIF":0.0,"publicationDate":"2000-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75723963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-10DOI: 10.5649/JJPHCS1975.26.438
Masaaki Takahashi, M. Hanaoka, S. Shimada, M. Nomura, H. Echizen
{"title":"Hemodializability of Pimobendan and Its Active Metabolite, UD-CG 212, in Patients with Congestive Heart Failure Undergoing Hemodialysis","authors":"Masaaki Takahashi, M. Hanaoka, S. Shimada, M. Nomura, H. Echizen","doi":"10.5649/JJPHCS1975.26.438","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.438","url":null,"abstract":"","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"49 1","pages":"438-442"},"PeriodicalIF":0.0,"publicationDate":"2000-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72869738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-08-10DOI: 10.5649/JJPHCS1975.26.432
M. Isawa, K. Yamazaki, K. Hattori, Ai Takahashi, K. Tada, F. Tsuchiya, E. Nakashima
We conducted a research survey on the management of patients with long-term withdrawal periods from drugs. The drug Didronel® was chosen as an example of a medicine with a withdrawal period. Questionnaires regarding the management of long-term withdrawal periods were given to both doctors and pharmacists. During the withdrawal period from Didronel®, the majority of the confirmation methods used by doctors were oral in nature. However, most of doctors considered a more ideal confirmation method to be the use of a medication diary. In the hospital, advice regarding Didronel® administration for the patients was mostly performed by doctors, followed by pharmacists and/or both. Many pharmacists gave an oral explanation of the withdrawal period, but only 13% used a medication diary. As a result, the persons responsible for managing the withdrawal period remained unclear. Moreover, a mere 3% of the hospitals provided information to outside pharmacies for discharged patient.
{"title":"An Investigation into the Current Management for Patients with Long-Term Withdrawal Periods from Drugs","authors":"M. Isawa, K. Yamazaki, K. Hattori, Ai Takahashi, K. Tada, F. Tsuchiya, E. Nakashima","doi":"10.5649/JJPHCS1975.26.432","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.432","url":null,"abstract":"We conducted a research survey on the management of patients with long-term withdrawal periods from drugs. The drug Didronel® was chosen as an example of a medicine with a withdrawal period. Questionnaires regarding the management of long-term withdrawal periods were given to both doctors and pharmacists. During the withdrawal period from Didronel®, the majority of the confirmation methods used by doctors were oral in nature. However, most of doctors considered a more ideal confirmation method to be the use of a medication diary. In the hospital, advice regarding Didronel® administration for the patients was mostly performed by doctors, followed by pharmacists and/or both. Many pharmacists gave an oral explanation of the withdrawal period, but only 13% used a medication diary. As a result, the persons responsible for managing the withdrawal period remained unclear. Moreover, a mere 3% of the hospitals provided information to outside pharmacies for discharged patient.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"3 1","pages":"432-437"},"PeriodicalIF":0.0,"publicationDate":"2000-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81378822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-10DOI: 10.5649/JJPHCS1975.26.316
T. Chikuma, Takeshi Shinoda, K. Taguchi, T. Ebihara, A. Tanaka, K. Kushida
The chemical stability of morphine hydrochloride in a total parenteral nutrient solution wasevaluated using a HPLC-ultraviolet detection system. This method is sensitive enough to measure morphine hydrochloride at concentrations as low as 0.2 nmol and produces highly reproducible results and requires 5.5 min per sample for separation and quantitation. Solutions of morphine hydrochloride in a total parenteral nutrient solution are chemically stable for 1 month when stored at 4°C and room temperature (20°C) with protection and no protection from environmental light. No loss of morphine hydrochloride due to adsorption in the polyethylene chloride (PEC) bags was found.
{"title":"Stability of Morphine Hydrochloride in a Total Parenteral Nutrient Solution","authors":"T. Chikuma, Takeshi Shinoda, K. Taguchi, T. Ebihara, A. Tanaka, K. Kushida","doi":"10.5649/JJPHCS1975.26.316","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.316","url":null,"abstract":"The chemical stability of morphine hydrochloride in a total parenteral nutrient solution wasevaluated using a HPLC-ultraviolet detection system. This method is sensitive enough to measure morphine hydrochloride at concentrations as low as 0.2 nmol and produces highly reproducible results and requires 5.5 min per sample for separation and quantitation. Solutions of morphine hydrochloride in a total parenteral nutrient solution are chemically stable for 1 month when stored at 4°C and room temperature (20°C) with protection and no protection from environmental light. No loss of morphine hydrochloride due to adsorption in the polyethylene chloride (PEC) bags was found.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"31 1","pages":"316-322"},"PeriodicalIF":0.0,"publicationDate":"2000-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72847270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-10DOI: 10.5649/JJPHCS1975.26.250
H. Endo, Yoshiteru Watanabe, M. Matsumoto, Shoichi Shirotake
The aim of the present study was to prepare a heat-sensitive melting gel using κ-carrageenan and gelatin as the gelation agents. The two agents have similar melting points (40-50°C for κ-carrageenan and 20-30°C for gelatin). When mixed together, they have a coexisting grid structure, which is favorable for the preparation of a gel with a melting temperature close to the human body temperature. Gel preparation showed a clearly different melting behavior from that of many other compounds and began to soften significantly below its melting temperature.κ-carrageenan at 0.5% may thus be the preferred concentration because preparations having a melting temperature just below the human body temperature are easy to chew, with a rapidly decreasing viscosity. We studied the plasma concentrations of acetaminophen as a function of time after the oral administration of a bulk powder or gel preparation of acetaminophen to rabbits after overnight fasting. A comparison of the AUC for both oral and intravenous administration indicated the bioavailability of acetaminophen gel to be about 90%. The heat-sensitive acetaminophen melting gel prepared using κ-carrageenan and gelatin thus shows promise for clinical use because of its favorable physicochemical and pharmaceutical characteristics.
{"title":"Preparation and Evaluation of Heat-sensitive Melting Gel","authors":"H. Endo, Yoshiteru Watanabe, M. Matsumoto, Shoichi Shirotake","doi":"10.5649/JJPHCS1975.26.250","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.250","url":null,"abstract":"The aim of the present study was to prepare a heat-sensitive melting gel using κ-carrageenan and gelatin as the gelation agents. The two agents have similar melting points (40-50°C for κ-carrageenan and 20-30°C for gelatin). When mixed together, they have a coexisting grid structure, which is favorable for the preparation of a gel with a melting temperature close to the human body temperature. Gel preparation showed a clearly different melting behavior from that of many other compounds and began to soften significantly below its melting temperature.κ-carrageenan at 0.5% may thus be the preferred concentration because preparations having a melting temperature just below the human body temperature are easy to chew, with a rapidly decreasing viscosity. We studied the plasma concentrations of acetaminophen as a function of time after the oral administration of a bulk powder or gel preparation of acetaminophen to rabbits after overnight fasting. A comparison of the AUC for both oral and intravenous administration indicated the bioavailability of acetaminophen gel to be about 90%. The heat-sensitive acetaminophen melting gel prepared using κ-carrageenan and gelatin thus shows promise for clinical use because of its favorable physicochemical and pharmaceutical characteristics.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"9 1","pages":"250-258"},"PeriodicalIF":0.0,"publicationDate":"2000-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88390880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-04-10DOI: 10.5649/JJPHCS1975.26.164
Moemi Saito, Machiko Watanabe, M. Hoshi, T. Mikawa, H. Yoshida, K. Edo
For the purpose of determining the shelf life of 1% Methylene Blue (MB) injection, its stability was investigated under 4 storage conditions for 30 weeks. The content of MB in 1% MB injection started to decrease at 5°C in the dark 4 weeks after preparation, but no significant differences were observed under three other storage conditions (at room temperature (22.0±0.5°C) and at 40°C in the dark and at room temperature (22.0±0.5°C) in 1000 Lux fluorescent light) for 30 weeks. According to these results, we changed the shelf life of 1% MB injection from 2 to 6 months and the frequency of preparation from six times to twice/year. The unit cost before and after the change of shelf life was compared. One unit cost calculated according to materials costs and labor costs was ¥2, 738.6 during the 1993-1995 period (six times preparations/year), while it was ¥1, 545.9 during the 1996-1998 period (twice preparations/year). A cost savings of ¥1, 192.7/ampule (43.6%) was produced by changing the frequency of preparation from six times to twice/year. In addition, the discard cost for 1% MB injection past its shelf life was estimated. A discard cost saving of ¥85, 766.8/year (75.2%) was achieved by changing the frequency of preparation from six times to twice/year. Furthermore, the working hours were reduced by 9.58 hours/man/year and it allowed pharmacists to utilize the extra time gained by changing the frequency to other work.
{"title":"Studies on Hospital Pharmaceutical Manufacturing (VI) Cost Comparison of Six Times versus Twice Per Year Preparations of 1% Methylene Blue Injection by a Cost Saving Analysis","authors":"Moemi Saito, Machiko Watanabe, M. Hoshi, T. Mikawa, H. Yoshida, K. Edo","doi":"10.5649/JJPHCS1975.26.164","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.164","url":null,"abstract":"For the purpose of determining the shelf life of 1% Methylene Blue (MB) injection, its stability was investigated under 4 storage conditions for 30 weeks. The content of MB in 1% MB injection started to decrease at 5°C in the dark 4 weeks after preparation, but no significant differences were observed under three other storage conditions (at room temperature (22.0±0.5°C) and at 40°C in the dark and at room temperature (22.0±0.5°C) in 1000 Lux fluorescent light) for 30 weeks. According to these results, we changed the shelf life of 1% MB injection from 2 to 6 months and the frequency of preparation from six times to twice/year. The unit cost before and after the change of shelf life was compared. One unit cost calculated according to materials costs and labor costs was ¥2, 738.6 during the 1993-1995 period (six times preparations/year), while it was ¥1, 545.9 during the 1996-1998 period (twice preparations/year). A cost savings of ¥1, 192.7/ampule (43.6%) was produced by changing the frequency of preparation from six times to twice/year. In addition, the discard cost for 1% MB injection past its shelf life was estimated. A discard cost saving of ¥85, 766.8/year (75.2%) was achieved by changing the frequency of preparation from six times to twice/year. Furthermore, the working hours were reduced by 9.58 hours/man/year and it allowed pharmacists to utilize the extra time gained by changing the frequency to other work.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"8 1","pages":"164-170"},"PeriodicalIF":0.0,"publicationDate":"2000-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77887850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sufficient drug informations should be provided to patients who place themselves under medical care regarding the proper use of drugs. Various reports have been published regarding what kind of drug information should be provided to outpatients. In our hospital, we meet these requirements by distributing of notebooks on the patients' medication history and medication cards. We have developed a system to prepare medication cards for a clinical consultation of inpatients using the database for outpatients, in order to efficiently individualize the medication cards according to each patients' disease. The accumulation and reproduction of individualized medication cards allows us to efficiently inform and educate inpatients about proper drug usage.
{"title":"個別化に対応した薬剤管理指導用「お薬説明書」作成システムの構築","authors":"恵子 新迫, 良子 石塚, 博子 若杉, 和伸 高柳, 亨 橋田, 高弘 二見, 雅弘 石津, 賢一 乾","doi":"10.5649/JJPHCS1975.26.177","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.177","url":null,"abstract":"Sufficient drug informations should be provided to patients who place themselves under medical care regarding the proper use of drugs. Various reports have been published regarding what kind of drug information should be provided to outpatients. In our hospital, we meet these requirements by distributing of notebooks on the patients' medication history and medication cards. We have developed a system to prepare medication cards for a clinical consultation of inpatients using the database for outpatients, in order to efficiently individualize the medication cards according to each patients' disease. The accumulation and reproduction of individualized medication cards allows us to efficiently inform and educate inpatients about proper drug usage.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"21 1","pages":"177-182"},"PeriodicalIF":0.0,"publicationDate":"2000-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90942761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-04-10DOI: 10.5649/JJPHCS1975.26.157
Mitsuru Machida, K. Sagawa, S. Murase, H. Kagaya, Haruko Kuzuyama, S. Shimada
The Ministry of Health and Welfare has issued a warning against carbapenem antibiotics regarding, their relationship to central convulsions and renal function, and also against histamine H2-receptor antagonists as well, regarding their relationship to renal dysfunction, hematological disorders, and other problems. Therefore, the careful administration of such drugs to prevent renal dysfunction is considered particularly important and strict guidelines for use of there drug have been developed but there has so far been no reports of institutional standardization of these guidelines. The Committee on the Promotion of the Appropriate Use of Medicines, which consists of physicians of various departments in our hospital, prepared unified drug administration guidelines for our hospital, and also examined their usefulness. As a result, these guidelines have proved to be useful, and were found to help reduce the overall health care costs.
{"title":"Construction and Evaluation of Common Guidelines for Recommended Dosage and Directions for the Use of Drugs in the Hospital","authors":"Mitsuru Machida, K. Sagawa, S. Murase, H. Kagaya, Haruko Kuzuyama, S. Shimada","doi":"10.5649/JJPHCS1975.26.157","DOIUrl":"https://doi.org/10.5649/JJPHCS1975.26.157","url":null,"abstract":"The Ministry of Health and Welfare has issued a warning against carbapenem antibiotics regarding, their relationship to central convulsions and renal function, and also against histamine H2-receptor antagonists as well, regarding their relationship to renal dysfunction, hematological disorders, and other problems. Therefore, the careful administration of such drugs to prevent renal dysfunction is considered particularly important and strict guidelines for use of there drug have been developed but there has so far been no reports of institutional standardization of these guidelines. The Committee on the Promotion of the Appropriate Use of Medicines, which consists of physicians of various departments in our hospital, prepared unified drug administration guidelines for our hospital, and also examined their usefulness. As a result, these guidelines have proved to be useful, and were found to help reduce the overall health care costs.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"17 1","pages":"157-163"},"PeriodicalIF":0.0,"publicationDate":"2000-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76007659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：